ABSTRACT
BACKGROUND: Quinidine gluconate, the only U.S. Food and Drug Administration-approved treatment for life-threatening malaria in the United States, has a problematic safety profile and is often unavailable in hospitals. OBJECTIVE: To assess the safety and clinical benefit of intravenous artesunate as an alternative to quinidine. DESIGN: Retrospective case series. SETTING: U.S. hospitals. PATIENTS: 102 patients aged 1 to 72 years (90% adults; 61% men) with severe and complicated malaria. Patients received 4 weight-based doses of intravenous artesunate (2.4 mg/kg) under a treatment protocol implemented by the Centers for Disease Control and Prevention between January 2007 and December 2010. At baseline, 35% had evidence of cerebral malaria, and 17% had severe hepatic impairment. Eligibility required the presence of microscopically confirmed malaria, need for intravenous treatment, and an impediment to quinidine. MEASUREMENTS: Clinical and laboratory data from each patient's hospital records were abstracted retrospectively, including information from baseline through a maximum 7-day follow-up, and presented before a physician committee to evaluate safety and clinical benefit outcomes. RESULTS: 7 patients died (mortality rate, 6.9%). The most frequent adverse events were anemia (65%) and elevated hepatic enzyme levels (49%). All deaths and most adverse events were attributed to the severity of malaria. Patients' symptoms generally improved or resolved within 3 days, and the median time to discharge from the intensive care unit was 4 days, even for patients with severe liver disease or cerebral malaria. More than 100 concomitant medications were used, with no documented drug-drug interactions. LIMITATION: Potential late-presenting safety issues might occur outside the 7-day follow-up. CONCLUSION: Artesunate was a safe and clinically beneficial alternative to quinidine.
Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Drugs, Investigational/therapeutic use , Malaria/drug therapy , Parasitemia/drug therapy , Adolescent , Adult , Aged , Antimalarials/adverse effects , Artemisinins/adverse effects , Artesunate , Child , Child, Preschool , Drug Therapy, Combination , Drugs, Investigational/adverse effects , Female , Humans , Infant , Injections, Intravenous , Malaria/complications , Male , Medication Adherence , Middle Aged , Parasitemia/complications , Retrospective Studies , Treatment Outcome , United States , Young AdultABSTRACT
BACKGROUND: We conducted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating weekly dosing in a human Plasmodium falciparum challenge model. METHODS: Thirty volunteers randomly received 1 of the following dose regimens: (1) 250 milligrams of atovaquone and 100 milligrams of proguanil (250/100 milligrams) 1 day prior to infectious mosquito challenge (day -1), (2) 250/100 milligrams on day 4 after challenge, (3) 250/100 milligrams on day -7, (4) 500 milligrams of atovaquone and 200 milligrams of proguanil (500/200 milligrams) on day -7 or, (5) 1000 milligrams of atovaquone and 400 milligrams of proguanil (1000/400 milligrams) on day -7. All regimens included matching placebo such that all volunteers received identical pill numbers. Six volunteers served as open-label infectivity controls. Volunteers underwent mosquito sporozoite challenge with P. falciparum 3D7 strain. Follow-up consisted of serial microscopy and close clinical monitoring for 90 days. RESULTS: Six of 6 infectivity controls developed parasitemia as expected. Two of 5 evaluable volunteers receiving 250/100 milligrams 7 days prior to challenge and 1 of 6 volunteers receiving 1000/400 milligrams 7 days prior to challenge were microscopically diagnosed with malaria. All other volunteers were protected. Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success). Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success). CONCLUSIONS: Single-dose atovaquone-proguanil provides effective malaria chemoprophylaxis against P. falciparum challenge at dosing intervals supportive of weekly dosing. Postexposure prophylaxis 4 days after challenge was 100% effective.
Subject(s)
Antimalarials/administration & dosage , Atovaquone/administration & dosage , Malaria, Falciparum/prevention & control , Plasmodium falciparum/drug effects , Proguanil/administration & dosage , Adult , Antimalarials/adverse effects , Antimalarials/pharmacokinetics , Area Under Curve , Atovaquone/adverse effects , Atovaquone/pharmacokinetics , Chemoprevention/methods , Cohort Studies , Drug Combinations , Female , Humans , Malaria, Falciparum/drug therapy , Malaria, Falciparum/metabolism , Male , Middle Aged , Parasitemia/drug therapy , Parasitemia/metabolism , Parasitemia/prevention & control , Placebos , Proguanil/adverse effects , Proguanil/pharmacokinetics , Sporozoites/drug effectsABSTRACT
Vector-borne infections (VBI) are defined as infectious diseases transmitted by the bite or mechanical transfer of arthropod vectors. They constitute a significant proportion of the global infectious disease burden. United States (U.S.) Department of Defense (DoD) personnel are especially vulnerable to VBIs due to occupational contact with arthropod vectors, immunological naiveté to previously unencountered pathogens, and limited diagnostic and treatment options available in the austere and unstable environments sometimes associated with military operations. In addition to the risk uniquely encountered by military populations, other factors have driven the worldwide emergence of VBIs. Unprecedented levels of global travel, tourism and trade, and blurred lines of demarcation between zoonotic VBI reservoirs and human populations increase vector exposure. Urban growth in previously undeveloped regions and perturbations in global weather patterns also contribute to the rise of VBIs. The Armed Forces Health Surveillance Center-Global Emerging Infections Surveillance and Response System (AFHSC-GEIS) and its partners at DoD overseas laboratories form a network to better characterize the nature, emergence and growth of VBIs globally. In 2009 the network tested 19,730 specimens from 25 sites for Plasmodium species and malaria drug resistance phenotypes and nearly another 10,000 samples to determine the etiologies of non-Plasmodium species VBIs from regions spanning from Oceania to Africa, South America, and northeast, south and Southeast Asia. This review describes recent VBI-related epidemiological studies conducted by AFHSC-GEIS partner laboratories within the OCONUS DoD laboratory network emphasizing their impact on human populations.
Subject(s)
Communicable Diseases, Emerging/epidemiology , Global Health , Malaria/epidemiology , Military Medicine , Sentinel Surveillance , Animals , Arthropod Vectors , Communicable Diseases, Emerging/transmission , Drug Resistance , Humans , United States , ZoonosesSubject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Drug Resistance , Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Animals , Antimalarials/administration & dosage , Artemisinins/administration & dosage , Cambodia , Humans , Inhibitory Concentration 50 , Kaplan-Meier Estimate , Plasmodium falciparum/isolation & purification , Quinine/therapeutic useABSTRACT
On December 26, 2004, an earthquake triggered a massive tsunami in the Indian Ocean, causing an estimated 183,172 deaths and 40,320 missing in 12 countries. In Thailand, six provinces (Krabi, Phang-Nga, Phuket, Ranong, Satun, and Trang) were affected. U.S. government agencies delivered emergency medical assistance from December 30, 2004, to January 6, 2005. A team from the Armed Forces Research Institute of Medical Sciences conducted a rapid health and needs assessment in southern Thailand. Twelve hospitals were referral centers for tsunami-related medical care. None of the hospitals had been damaged during the tsunami; all activated mass casualty plans. As of October 2005, 5,395 deaths were confirmed and 2,817 individuals were missing. The response of the Thai government to the tsunami was rapid and effective in mitigating the health consequences among survivors and helped prioritize public health interventions and the diversion of U.S. assistance to areas with greater need for international emergency humanitarian assistance.
Subject(s)
Altruism , Disaster Planning/organization & administration , Disasters , Emergency Medical Services/organization & administration , Health Services Needs and Demand , Medical Missions/organization & administration , Military Medicine/organization & administration , Public Health Administration , Relief Work/organization & administration , Emergency Medical Services/supply & distribution , Health Care Surveys , Hospitals, Public/organization & administration , Humans , Needs Assessment , Thailand , Time Factors , United StatesABSTRACT
BACKGROUND: Little is known about diarrhea etiology and antibiotic resistance in developing countries where diarrhea is a major public health problem. METHODS: To describe diarrhea etiology and antibiotic resistance patterns in Cambodia, 600 children aged 3 months to 5 years with acute diarrhea (cases) and 578 children without diarrhea (controls) were enrolled from a hospital in Phnom Penh. Stool samples were collected, and pathogens and antibiotic resistance patterns were described. RESULTS: The most frequently isolated pathogens in these cases were enteroaggregative Escherichia coli (20%) and rotavirus (26%). Enterotoxigenic E. coli, enteroaggregative E. coli, Shigella, Aeromonas, rotavirus, and adenovirus were statistically significantly associated with diarrhea. Among cases, vomiting was associated with viral infections, whereas bloody stool was associated with Shigella. Enterotoxigenic E. coli isolates were highly resistant to ampicillin, sulfonamides, and tetracycline. Approximately 50% of Campylobacter coli and 30% of Campylobacter jejuni isolates were resistant to nalidixic acid and ciprofloxacin. Over 33% of Salmonella isolates were resistant to ampicillin and tetracycline, and almost 100% of Shigella isolates were resistant to trimethoprim/sulfamethoxazole. CONCLUSIONS: These data on the etiology of diarrhea and antibiotic resistance patterns in Cambodia will have significant effect on local public health policies and on local resource prioritization practices.
Subject(s)
Bacteria/drug effects , Bacterial Infections/epidemiology , Bacterial Infections/microbiology , Diarrhea/epidemiology , Drug Resistance, Bacterial , Virus Diseases/epidemiology , Virus Diseases/virology , Anti-Bacterial Agents/pharmacology , Bacteria/isolation & purification , Cambodia/epidemiology , Child, Preschool , Diarrhea/microbiology , Diarrhea/virology , Feces/microbiology , Feces/virology , Female , Humans , Infant , Male , Microbial Sensitivity Tests , Prevalence , Viruses/isolation & purificationABSTRACT
Mixed P. falciparum/P. vivax infections are common in southeast Asia. When patients with P. falciparum malaria are treated and followed for several weeks, a significant proportion will develop P. vivax malaria. In a combined analysis of 243 patients recruited to two malaria treatment trials in western Cambodia, 20/43 (47%) of those with P. falciparum gametocytes on admission developed P. vivax malaria by Day 28 of follow-up. The presence of Pf gametocytes on an initial blood smear was associated with a 3.5-fold greater rate of vivax parasitemia post-treatment (IRRâ=â3.5, 95% CI 2.0-6.0, p<0.001). The increased rate of post-treatment P. vivax infection persisted when correlates of exposure and immunity such as a history of malaria, male gender, and age were controlled for (IRRâ=â3.0, 95% CI 1.9-4.7, p<0.001). Polymerase chain reaction (PCR) confirmed that only a low proportion of subjects (5/55 or 9.1%) who developed vivax during follow-up had detectable Pv parasites in the peripheral blood at baseline. Molecular detection of falciparum gametocytes by reverse transcriptase PCR in a subset of patients strengthened the observed association, while PCR detection of Pv parasitemia at follow-up was similar to microscopy results. These findings suggest that the majority of vivax infections arising after treatment of falciparum malaria originate from relapsing liver-stage parasites. In settings such as western Cambodia, the presence of both sexual and asexual forms of P. falciparum on blood smear at presentation with acute falciparum malaria serves as a marker for possible occult P. vivax coinfection and subsequent relapse. These patients may benefit from empiric treatment with an 8-aminoquinolone such as primaquine.